April 22, 2024

Webinar: Advancing in vitro high-throughput transcriptomics for chemical toxicity testing

Webinar: Advancing in vitro high-throughput transcriptomics for chemical toxicity testing
About this webinar

Toxicity testing is on the cusp of transitioning away from expensive and ethically challenged animal-based methods, towards more efficient alternative approaches. Concurrently, advances in technologies that examine sub-lethal effects on gene expression have led to increased interest in the concept of transcriptomic points of departure (tPODs), or the threshold concentration beyond which a concerted response in gene expression may be expected, indicating the potential for adverse effects at the organismal level.

These concentrations have been found to be lower than (i.e. protective of) benchmark effect concentrations that can cause mortality and reproductive defects. Consequentially, there is growing scientific and regulatory interest in tPODs for applications in chemical screening and prioritization.

Hear from researchers from McGill University, as they present case studies in optimizing and advancing efficient workflows that couple in vitro exposures with ultraplexed library preparation using the QIAseq UPXome RNA Library Kit. This approach has increased the throughput of differential expression and dose-response analysis for tPODs derivation.

Additionally, learn how combining ultraplexed library preparation with mosquito® automated liquid handling has improved efficiency in two ways:

  • Shortening the overall library preparation protocol time
  • Reducing reagent usage by a half by miniaturizing protocol volumes
register now

Our latest News

discover more
Globally influential: Professor Auffarth once again on ophthalmology’s “Power List”

Globally influential: Professor Auffarth once again on ophthalmology’s “Power List”

Professor Dr. Gerd Auffarth continues to be one of the world’s leading ophthalmologists, according to “The Ophthalmologist”. The journal has now published its “Power List 2025” of the most influential representatives of the field. The Medical Director of the Eye Clinic at Heidelberg University Hospital (UKHD) has now been named on the list for the […]

3D bioprinting: NMI, TU Darmstadt and Black Drop develop improved bioink

3D bioprinting: NMI, TU Darmstadt and Black Drop develop improved bioink

Joint press release by the NMI and the Technical University of Darmstadt (How) can we 3D print tissues that mimic the complex anatomy of natural body tissue as closely as possible? 3D bioprinting is a great hope in the field of regenerative medicine to produce miniaturized tissues and organ precursors with biological functionality. Today, however, […]

Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies. ZURICH, SWITZERLAND, and BROOKLYN, NEW YORK, USA, April 23, 2025 — VERAXA Biotech AG(“VERAXA” or the “Company”), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp